Novavax sees weak Covid vaccine sales
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
There are three types of vaccines available in the United States — Pfizer-BioNTech, Moderna and Novavax ... was the first COVID vaccine to receive FDA Emergency Use Authorization from the ...
Dr. Marty discusses why the FDA put a hold on the Novavax COVID-Flu vaccines and how their COVID vaccine is different from the others that are offered. She also explains the possible ...
Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on GeoVax Labs (GOVX – Research Report). The associated ...
(The Novavax vaccine works in a similar way to the mRNA vaccines — it just skips the step of having cells make spike protein, since the vaccine itself contains protein.) The company did not ...
(Bloomberg) -- Novavax Inc. shares fell 19% after US regulators placed a hold on the company’s experimental vaccines because a study volunteer developed a serious nerve disorder. The pause ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback